Ovarian Cancer: New Therapeutic Concepts, Renewed Optimism
Authors: FRANCO M. MUGGIA
Journal: Annals of Internal Medicine (1985)

Editorials1 November 1985Ovarian Cancer: New Therapeutic Concepts, Renewed OptimismFRANCO M. MUGGIA, M.D., MARTINE J. PICCART, M.D., JAMES L. SPEYER, M.D.FRANCO M. MUGGIA, M.D.Search for more papers by this author, MARTINE J. PICCART, M.D.Search for more papers by this author, JAMES L. SPEYER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-103-5-795 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptEpithelial carcinomas of the ovary are the most commonly fatal malignancies arising in gynecologic organs of women in developed countries. Because initial clinical manifestations in more than half of the afflicted women are subtle, discovery of the disease most often occurs in stages involving extrapelvic spread. When biologically malignant, ovarian cancer spreads predominantly by the shedding of cells into the peritoneal cavity and establishment of serosal implants initially distributed to the omentum, pelvic reflections, and diaphragmatic gutters. The factors responsible for development of serosal and other peritoneal tumors, their evolution from premalignant to invasive lesions, and the peculiar biology imparting...References1. BUICKPOLLAK RM. Perspectives on clonogenic tumor cells, stem cells, and oncogenes. Cancer Res. 1984;44:4909-18. MedlineGoogle Scholar2. FEIGBASTKNAPPCOOPER LRRG. Somatic activation of rasK gene in a human ovarian carcinoma. Science. 1984;223:698-701. CrossrefMedlineGoogle Scholar3. FRIEDLANDERTAYLORRUSSELLMUSGROVEHEDLEYTATTERSALL MIPEDM. Ploidy as a prognostic factor in ovarian cancer. Int J Gynecol Pathol. 1983;2:55-63. CrossrefMedlineGoogle Scholar4. HAMILTONYOUNGOZOLS TRR. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin Oncol. 1984;11:285-98. MedlineGoogle Scholar5. BELLGERLACHKARTNERBUICKLING DJNRV. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol. 1985;3:311-5. CrossrefMedlineGoogle Scholar6. BRODOVSKYBAUERHORTONELSON HMJP. Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer. Cancer. 1984;53:844-52. CrossrefMedlineGoogle Scholar7. YOUNGCHABNERHUBBARD RBS Advanced ovarian adenocarcinoma: a prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978;299:1261-6. CrossrefMedlineGoogle Scholar8. VOGLPAGANOKAPLAN SMB. Cyclophosphamide, hexamethylmelamine, adriamycin, and diammine dichloroplatinum "CHAD" vs. melphalan for advanced ovarian cancer: a randomized prospective trial of the Eastern Cooperative Oncology Group [Abstract]. Proc Am Soc Clin Oncol. 1981;22:473. Google Scholar9. PICCARTSPEYERWERNZ MJJ Advanced epithelial ovarian cancer (OV-CA): update with impressive survival utilizing cisplatin (DDP) (100 mg/m2/cycle) and cyclophosphamide (CTX) [Abstract]. Proc Am Soc Clin Oncol. 1985;4:117. Google Scholar10. NEIJTTENHUININKVANDER BURG JBWM Combination chemotherapy with CHAP-5 and CP in advanced ovarian carcinoma: a randomized trial of the Netherlands Joint Study Group for Ovarian Cancer [Abstract]. Proc Am Soc Clin Oncol. 1985;4:114. Google Scholar11. WHITLEYBRENNERFRANCIS NDA Use of the computed tomographic whole body scanner to stage and follow patients with advanced ovarian carcinoma. Invest Radiol. 1981;16:479-86. CrossrefMedlineGoogle Scholar12. BASTKLUGST JOHN RTE A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-7. CrossrefMedlineGoogle Scholar13. COLOMBOROVELLIVASSENA NFL Monitoring CA125 serum levels (SL) to predict treatment outcome in ovarian cancer patients (OCP) [Abstract]. Proc Am Assoc Cancer Res. 1985;26:146. Google Scholar14. PICCARTGOLDHIRSCHDAVIS MAB A prospective study of the correlation between CA125 serum levels and surgically verified tumor burden in ovarian cancer (OV-CA) patients (pts) [Abstract]. Proc Am Assoc Cancer Res. 1985;26:148. Google Scholar15. BASTKNAPP RR. Immunologic approaches to the management of ovarian carcinoma. Semin Oncol. 1984;11:264-74. MedlineGoogle Scholar16. MANTOVANIALLAVENASESSABOLISMANGIONI APCGC. Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors. Int J Cancer. 1980;25:573-82. CrossrefMedlineGoogle Scholar17. HAINSWORTHMALCOLMJOHNSONBURNETTJONESGRECO JADLHF. Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy. Obstet Gynecol. 1983;61:619-23. MedlineGoogle Scholar18. DEMBOBUSHBEALEBEANPRINGLESTURGEON ARFHJJ. The Princess Margaret Hospital Study of Ovarian Cancer: stages I, II, and asymptomatic III presentations. Cancer Treat Rep. 1979;63:249-54. MedlineGoogle Scholar19. GRECOJULIANRICHARDSONBURNETTHANDEOLDHAM FCRLKR. Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation. Obstet Gynecol. 1981;58:199-205. MedlineGoogle Scholar20. BRUCKNERCOHENGOLDBERG HCJ Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer. Am J Obstet Gynecol. 1983;145:653-8. CrossrefMedlineGoogle Scholar21. DOUPLERICHMOND ER. Platinum complexes as radiosensitizers of hypoxic mammalian cells. Br J Cancer [Suppl]. 1978;37:98-102. Google Scholar22. OZOLSCORDENJACOBWESLEYOSTCHEGAYOUNG RBJMYR. High-dose cisplatin in hypertonic saline. Ann Intern Med. 1984;100:19-24. LinkGoogle Scholar23. HACKERDOUPLEKRAKOFF MEI eds. Platinum Coordination Complexes in Cancer Chemotherapy. Boston: Martinus Nijhoff; 1984. CrossrefGoogle Scholar24. SESSACAVALLIKAYE CFS Phase II study of cis-dichlorotrans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in advanced ovarian carcinoma [Abstract]. Proc Am Soc Clin Oncol. 1985;4:116. Google Scholar25. WILTSHAWEVANSHARLAND EBS. Phase III randomized trial cisplatin versus JM8 (carboplatin) in 112 ovarian cancer patients, stages III and IV [Abstract]. Proc Am Soc Clin Oncol. 1985;4:121. Google Scholar26. DEDRICKMYERSBUNGAYDEVITA RCPV Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1-11. MedlineGoogle Scholar27. OZOLSMYERSYOUNG RCR. Intraperitoneal chemotherapy [Editorial]. Ann Intern Med. 1984;101:118-20. LinkGoogle Scholar28. HOWELLPFEIFLEWUNGOLSHEN SCWR. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res. 1983;43:1426-31. MedlineGoogle Scholar29. MCVIETENHUININKAARTSENSIMONETTIDUBBELMANFRANKLIN JBWEGRH. Intraperitoneal chemotherapy in minimal residual ovarian cancer with cisplatin and IV sodium thiosulfate protection [Abstract]. Proc Am Soc Clin Oncol. 1985;4:125. Google Scholar30. HOWELLPFEIFLEOLSHEN SCR. Intraperitoneal chemotherapy with melphalan. Ann Intern Med. 1984;101:14-8. LinkGoogle Scholar31. MARKMANCLEARYLUCASHOWELL MSWS. Combination intraperitoneal (IP) chemotherapy with cisplatin (DDP), cytarabine (ara-C) and bleomycin (Bleo) [Abstract]. Proc Am Soc Clin Oncol. 1985;4:112. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: FRANCO M. MUGGIA, M.D.; MARTINE J. PICCART, M.D.; JAMES L. SPEYER, M.D.Affiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMetastatic Cancer from Unknown Primary SiteGeneral Issues in Anticancer Drug Development 1 November 1985Volume 103, Issue 5Page: 795-797KeywordsCellsLesionsOvarian cancerOvaries ePublished: 1 December 2008 Issue Published: 1 November 1985 PDF downloadLoading ...